ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News) announced initiation of its global Phase 3 clinical trial of oral deforolimus in patients with metastatic soft-tissue and bone sarcomas. This pivotal trial will assess progression-free survival (PFS) as the primary endpoint and overall survival as a secondary endpoint in patients with metastatic sarcomas following a favorable response to chemotherapy. [click link for full article]

More: continued here

This entry was posted on Friday, September 28th, 2007 at 6:09 am and is filed under Bones. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.